Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18672944 | COMPOSITIONS AND METHODS OF EXPANSION OF T CELL POPULATIONS | May 2024 | December 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18513069 | CONSTRUCTION METHOD AND APPLICATION OF OVARIAN GRANULOSA CELL LINE OF ONCORHYNCHUS MYKISS | November 2023 | February 2025 | Abandon | 15 | 2 | 0 | No | No |
| 18501269 | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND METHODS THEREOF | November 2023 | June 2024 | Allow | 7 | 0 | 0 | No | No |
| 18459302 | METHODS OF USE FOR CAR T CELLS | August 2023 | November 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18033536 | HYDROGEL COMPOSITIONS AND METHODS OF USE THEREOF | April 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 17932857 | ENHANCING ANTI-TUMOR RESPONSE IN MELANOMA CELLS WITH DEFECTIVE STING SIGNALING | September 2022 | November 2025 | Allow | 38 | 0 | 0 | No | No |
| 17910931 | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13RALPHA2 POSITIVE MALIGNANCIES | September 2022 | September 2025 | Allow | 37 | 0 | 0 | No | No |
| 17910304 | MITOCHONDRIA-ENRICHED GENETICALLY ENGINEERED CELLS AND USES THEREOF | September 2022 | March 2026 | Allow | 42 | 1 | 0 | No | No |
| 17905134 | COBRA1/NELF-B AS A BOOSTER FOR EFFICACY OF CD8+ T CELL-BASED THERAPY | August 2022 | January 2026 | Allow | 41 | 1 | 0 | No | No |
| 17904223 | USE OF EARLY APOPTOTIC CELLS FOR TREATING COVID-19 | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17862797 | METHODS FOR ENHANCING EFFICACY OF THERAPEUTIC IMMUNE CELLS | July 2022 | May 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17857495 | MESENCHYMAL STEM CELLS FOR USE IN THE TREATMENT OF ATOPIC DERMATITIS | July 2022 | March 2025 | Allow | 32 | 3 | 0 | No | No |
| 17790041 | METHOD FOR PURIFYING UCART CELL AND USE THEREOF | June 2022 | February 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17780945 | COMPOSITIONS AND METHODS FOR THE TARGETING OF RHODOPSIN | May 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17780617 | METHOD FOR OBTAINING CAR-NK CELLS | May 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17716029 | INJECTABLE OFF-THE- SHELF CARTILAGE, TENDON, AND LIGAMENT REPAIR COMPOSITIONS AND METHODS OF USE | April 2022 | August 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17753364 | CD25 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | February 2022 | December 2025 | Allow | 46 | 1 | 0 | No | No |
| 17277142 | CHEMOKINE EXPRESSING CELL AND USE THEREOF | December 2021 | November 2025 | Abandon | 56 | 0 | 1 | No | No |
| 17619158 | CD52-DEFICIENT CELLS FOR ADOPTIVE CELL THERAPY | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17617632 | CIRCULAR RNAS FOR CELLULAR THERAPY | December 2021 | December 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17614421 | CD8+ T-CELLS LACKING PLEXINS AND THEIR APPLICATION IN CANCER TREATMENT | November 2021 | July 2025 | Allow | 44 | 1 | 1 | No | No |
| 17613586 | AUTOLOGOUS CELL REPLACEMENT THERAPY FOR PARKINSON`S DISEASE | November 2021 | November 2025 | Allow | 48 | 1 | 1 | No | No |
| 17611542 | ENGINEERED IMMUNE CELLS COMPRISING A RECOGNITION MOLECULE | November 2021 | October 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17609507 | TARGETING OTUB1 IN IMMUNOTHERAPY | November 2021 | August 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17513034 | Platform Oncolytic Vector for Systemic Delivery | October 2021 | September 2024 | Allow | 35 | 8 | 1 | Yes | No |
| 17600987 | SERUM-FREE CRYOPRESERVATION SOLUTION AND PREPARATION METHOD AND APPLICATION THEREOF | October 2021 | July 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17593391 | PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY | September 2021 | June 2025 | Allow | 45 | 1 | 0 | No | No |
| 17470697 | METHOD FOR PREPARING CELL EXTRACT COMPONENT OR COMPOSITION HAVING CYTOCIDAL ACTIVITY | September 2021 | January 2024 | Allow | 28 | 1 | 0 | No | No |
| 17465093 | CAR-T CELLS WITH HUMANIZED CD19 SCFV | September 2021 | May 2024 | Allow | 33 | 0 | 0 | No | No |
| 17435485 | GENOME-EDITED BIRDS | September 2021 | April 2025 | Allow | 43 | 2 | 0 | No | No |
| 17435175 | COMPOSITION FOR USE IN TREATMENT OF ALLERGIC DISEASES | August 2021 | December 2025 | Allow | 52 | 2 | 2 | No | No |
| 17410594 | T CELLS WITH IMPROVED FUNCTIONALITY | August 2021 | July 2024 | Allow | 35 | 2 | 1 | No | No |
| 17431992 | CO-CULTURING DEVICE, MOTOR NEURON CULTURING DEVICE, MULTI-WELL PLATE, FABRICATION METHOD OF IN VITRO EVALUATION MODEL OF NEUROMUSCULAR DISEASE, AND SCREENING METHOD OF THERAPEUTIC AGENT AGAINST NEUROMUSCULAR DISEASE | August 2021 | March 2026 | Allow | 55 | 2 | 1 | No | No |
| 17399993 | CR3022 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | August 2021 | March 2024 | Allow | 31 | 2 | 0 | No | No |
| 17397174 | MATERIALS AND METHODS FOR PRODUCING BIOENGINEERED VIRUS SPECIFIC LYMPHOCYTES | August 2021 | August 2025 | Allow | 48 | 4 | 1 | No | No |
| 17425498 | Compositions and Methods for Targeting Mutant RAS | July 2021 | September 2025 | Allow | 50 | 1 | 1 | No | No |
| 17383279 | METHODS FOR GENERATING, EVALUATING, GENE EDITING AND CLONING PLURIPOTENT STEM CELLS COMPRISING A LETHAL HAPLOTYPE | July 2021 | June 2024 | Allow | 35 | 2 | 0 | No | No |
| 17381693 | CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED SIGNALING AND ACTIVITIES AND USES THEREOF | July 2021 | September 2024 | Allow | 38 | 4 | 0 | No | No |
| 17421287 | IMPROVED TARGETED T-CELL THERAPY FOR TREATMENT OF MULTIPLE MYELOMA | July 2021 | November 2025 | Allow | 52 | 2 | 1 | No | No |
| 17416739 | TRANSGENIC MOUSE EXPRESSING COMMON HUMAN LIGHT CHAIN | June 2021 | July 2025 | Allow | 49 | 2 | 0 | No | No |
| 17353388 | LASER TREATED PLATELET PRODUCT | June 2021 | February 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17415957 | PRODUCTION AND THERAPEUTIC USE OF OFF-THE-SHELF DOUBLE NEGATIVE T CELLS | June 2021 | September 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17348048 | THERAPY | June 2021 | February 2024 | Allow | 32 | 2 | 0 | No | No |
| 17311210 | BIOMARKER | June 2021 | June 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17294477 | USE OF IRE1ALPHA-XBP1 SIGNALING PATHWAY BIOMARKERS FOR MODULATING IMMUNE RESPONSES | May 2021 | September 2024 | Allow | 40 | 1 | 1 | No | No |
| 17290710 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | April 2021 | December 2025 | Allow | 55 | 2 | 1 | No | No |
| 17237087 | Clinical Gene Signature-Based Human Cell Culture Model and Uses Thereof | April 2021 | July 2025 | Allow | 51 | 4 | 0 | Yes | No |
| 17232588 | SYSTEMS AND METHODS FOR IMMOBILIZING EXTRACELLULAR MATRIX MATERIAL ON ORGAN ON CHIP, MULTILAYER MICROFLUIDICS MICRODEVICES, AND THREE-DIMENSIONAL CELL CULTURE SYSTEMS | April 2021 | October 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17280498 | TREATMENT METHODS | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17279697 | POLYNUCLEOTIDES ENCODING ARGINASE 1 FOR THE TREATMENT OF ARGINASE DEFICIENCY | March 2021 | September 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17172150 | CANCER TREATMENT USING BETA-(1-3)-(1-4)-GLUCAN | February 2021 | July 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17154192 | ENHANCING ANTI-TUMOR RESPONSE IN MELANOMA CELLS WITH DEFECTIVE STING SIGNALING | January 2021 | December 2025 | Allow | 59 | 4 | 0 | Yes | No |
| 17254110 | METHOD FOR ELICITING INFECTIOUS IMMUNOLOGICAL TOLERANCE | December 2020 | November 2024 | Allow | 47 | 2 | 1 | No | No |
| 17127496 | ANIMAL MODEL FOR HEPATOCELLULAR CARCINOMA AND USES THEREOF | December 2020 | March 2025 | Allow | 51 | 1 | 1 | No | No |
| 17254094 | ANTIBODY CAPABLE OF INDUCING IMMUNE TOLERANCE PRODUCED USING CELL MIXTURE HAVING COMPLEXED STATE, AND INDUCED LYMPHOCYTE OR CELL THERAPEUTIC AGENT AND CELL THERAPY METHOD EACH USING INDUCED LYMPHOCYTE | December 2020 | April 2025 | Allow | 52 | 2 | 1 | No | No |
| 17251666 | MITOCHONDRIAL AUGMENTATION THERAPY OF RENAL DISEASES | December 2020 | May 2025 | Allow | 53 | 3 | 0 | No | No |
| 17111332 | Bacteria-Based Protein Delivery | December 2020 | May 2024 | Allow | 42 | 2 | 0 | No | No |
| 17057206 | CELL THERAPY | November 2020 | September 2025 | Abandon | 58 | 4 | 0 | No | No |
| 17083211 | TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR | October 2020 | February 2025 | Allow | 52 | 1 | 0 | No | No |
| 17048248 | T-CELL EXHAUSTION, METHODS & COMPOSITIONS RELATING THERETO | October 2020 | September 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17045562 | Humanized Mouse Model | October 2020 | June 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17042022 | USE OF HISTONE MODIFIERS TO REPROGRAM EFFECTOR T CELLS | September 2020 | August 2024 | Allow | 47 | 1 | 1 | No | No |
| 16982640 | GENE THERAPEUTICS FOR TREATING BONE DISORDERS | September 2020 | September 2024 | Allow | 56 | 2 | 0 | No | No |
| 16982881 | NOVEL METHOD FOR OBTAINING T CELLS FROM PLURIPOTENT STEM CELLS, AND USES THEREOF | September 2020 | May 2024 | Allow | 44 | 1 | 1 | No | No |
| 16982984 | CANCER THERAPY | September 2020 | March 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 16982531 | CLEAN SPACE MAINTENANCE STRUCTURE, AND CELL PRODUCTION OR CULTURING METHOD | September 2020 | November 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16980782 | MACROPHAGE-BASED THERAPY | September 2020 | February 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 16980200 | PROCESS FOR PRODUCING CARDIAC ORGANOIDS | September 2020 | September 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16978735 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION | September 2020 | April 2025 | Allow | 55 | 3 | 1 | No | No |
| 16978407 | INJECTABLE OFF-THE- SHELF CARTILAGE, TENDON, AND LIGAMENT REPAIR COMPOSITIONS AND METHODS OF USE | September 2020 | September 2025 | Allow | 60 | 3 | 1 | No | No |
| 16977517 | IDENTIFYING AND CHARACTERIZING GENOMIC SAFE HARBORS (GSH) IN HUMANS AND MURINE GENOMES, AND VIRAL AND NON-VIRAL VECTOR COMPOSITIONS FOR TARGETED INTEGRATION AT AN IDENTIFIED GSH LOCI | September 2020 | November 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16993692 | METHOD FOR INDUCING RNA SILENCING | August 2020 | November 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16943400 | Methods for Enhancing Efficacy of Therapeutic Immune Cells | July 2020 | May 2025 | Allow | 58 | 2 | 1 | Yes | No |
| 16965955 | ICAM-1 MARKER AND APPLICATION THEREOF | July 2020 | June 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16938132 | ANTIBODY GENE EDITING IN B LYMPHOCYTES | July 2020 | July 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16931986 | LENTIVIRAL VECTORS FOR REGULATED EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR MOLECULE | July 2020 | August 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16960504 | COMPOSITIONS AND METHODS OF EXPANSION OF T CELL POPULATIONS | July 2020 | February 2024 | Allow | 44 | 2 | 1 | No | No |
| 16958118 | METHOD FOR PREPARING FUNCTIONAL HEPATIC PROGENITOR CELLS OR HEPATIC CELLS, OR FUNCTIONAL SMALL INTESTINAL EPITHELIAL PROGENITOR CELLS OR SMALL INTESTINAL EPITHELIAL CELLS | June 2020 | July 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16956894 | CONSTRUCTS COMPRISING NEURONAL VIABILITY FACTORS AND USES THEREOF | June 2020 | May 2024 | Allow | 47 | 1 | 0 | No | No |
| 16900731 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | June 2020 | February 2025 | Abandon | 56 | 2 | 2 | No | No |
| 16769821 | NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN AND USES THEREOF | June 2020 | December 2024 | Abandon | 55 | 4 | 1 | No | No |
| 16658197 | Culture System and Media for Skin Explants Providing Enhanced Viability and Enabling Molecular Studies | October 2019 | November 2024 | Allow | 60 | 5 | 1 | No | No |
| 16476628 | MODIFIED T CELLS AND METHODS OF THEIR USE | July 2019 | July 2025 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16335884 | METHOD FOR PREPARING A SUPPLEMENT FROM MESENCHYMAL CELL CULTURES OF WHARTON'S JELLY AND USES OF SAME | May 2019 | June 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16302865 | Gene Therapy Methods for Age-Related Diseases and Conditions | November 2018 | August 2024 | Allow | 60 | 7 | 0 | Yes | No |
| 16092841 | METHODS FOR CREATING SYNTHETIC CHROMOSOMES HAVING GENE REGULATORY SYSTEMS AND USES THEREOF | October 2018 | October 2025 | Allow | 60 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AMICK, THOMAS RUSSE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AMICK, THOMAS RUSSE works in Art Unit 1638 and has examined 69 patent applications in our dataset. With an allowance rate of 69.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 49 months.
Examiner AMICK, THOMAS RUSSE's allowance rate of 69.6% places them in the 32% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by AMICK, THOMAS RUSSE receive 2.13 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by AMICK, THOMAS RUSSE is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +38.2% benefit to allowance rate for applications examined by AMICK, THOMAS RUSSE. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.8% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.4% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.4% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 16.7% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.